Sangamo Therapeutics Sets June 4th Virtual Annual Meeting
Ticker: SGMO · Form: DEF 14A · Filed: Apr 19, 2024 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | DEF 14A |
| Filed Date | Apr 19, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 20 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
Related Tickers: SGMO
TL;DR
SGMO annual meeting June 4th, virtual only. Vote directors.
AI Summary
Sangamo Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 4, 2024, at 8:30 a.m. Pacific Time. The primary purpose is to elect nine director nominees to serve on the Board of Directors until the 2025 annual meeting. The meeting will be conducted via live webcast at meetnow.global/MJQ9LPD, and in-person attendance will not be possible.
Why It Matters
This proxy statement outlines key corporate governance matters, including director elections, which directly impact the company's strategic direction and oversight.
Risk Assessment
Risk Level: low — This filing is a standard proxy statement for an annual meeting and does not contain new material financial or operational information that would typically indicate high risk.
Key Numbers
- 9 — Director Nominees (To be elected at the Annual Meeting)
Key Players & Entities
- Sangamo Therapeutics, Inc. (company) — Registrant
- June 4, 2024 (date) — Annual Meeting Date
- 8:30 a.m. Pacific Time (time) — Annual Meeting Time
- meetnow.global/MJQ9LPD (url) — Virtual Meeting Location
FAQ
What is the date and time of Sangamo Therapeutics' 2024 Annual Meeting of Stockholders?
The 2024 Annual Meeting of Stockholders will be held on Tuesday, June 4, 2024, at 8:30 a.m. Pacific Time.
How will the 2024 Annual Meeting of Stockholders be conducted?
The Annual Meeting will be held in an online-only format through a live webcast at meetnow.global/MJQ9LPD.
Can stockholders attend the 2024 Annual Meeting in person?
No, stockholders will not be able to attend the meeting in person.
What is the primary purpose of the 2024 Annual Meeting?
The primary purpose is to elect nine nominees for director to serve on the Board of Directors until the next annual meeting of stockholders in 2025.
What is the name of the company filing this proxy statement?
The name of the company filing this proxy statement is Sangamo Therapeutics, Inc.
Filing Stats: 4,897 words · 20 min read · ~16 pages · Grade level 12.2 · Accepted 2024-04-19 16:01:45
Filing Documents
- sgmo-20240419.htm (DEF 14A) — 1763KB
- sgmo-20240419_g1.jpg (GRAPHIC) — 656KB
- sgmo-20240419_g10.jpg (GRAPHIC) — 120KB
- sgmo-20240419_g11.jpg (GRAPHIC) — 108KB
- sgmo-20240419_g12.jpg (GRAPHIC) — 166KB
- sgmo-20240419_g13.jpg (GRAPHIC) — 124KB
- sgmo-20240419_g14.jpg (GRAPHIC) — 105KB
- sgmo-20240419_g15.jpg (GRAPHIC) — 130KB
- sgmo-20240419_g16.jpg (GRAPHIC) — 93KB
- sgmo-20240419_g17.jpg (GRAPHIC) — 170KB
- sgmo-20240419_g18.jpg (GRAPHIC) — 93KB
- sgmo-20240419_g19.jpg (GRAPHIC) — 687KB
- sgmo-20240419_g2.jpg (GRAPHIC) — 244KB
- sgmo-20240419_g20.jpg (GRAPHIC) — 134KB
- sgmo-20240419_g21.gif (GRAPHIC) — 17KB
- sgmo-20240419_g22.jpg (GRAPHIC) — 34KB
- sgmo-20240419_g23.jpg (GRAPHIC) — 165KB
- sgmo-20240419_g24.jpg (GRAPHIC) — 120KB
- sgmo-20240419_g25.jpg (GRAPHIC) — 276KB
- sgmo-20240419_g26.jpg (GRAPHIC) — 278KB
- sgmo-20240419_g3.jpg (GRAPHIC) — 670KB
- sgmo-20240419_g4.jpg (GRAPHIC) — 920KB
- sgmo-20240419_g5.jpg (GRAPHIC) — 696KB
- sgmo-20240419_g6.jpg (GRAPHIC) — 22KB
- sgmo-20240419_g7.gif (GRAPHIC) — 17KB
- sgmo-20240419_g8.jpg (GRAPHIC) — 103KB
- sgmo-20240419_g9.jpg (GRAPHIC) — 138KB
- 0001628280-24-016932.txt ( ) — 17066KB
- sgmo-20240419.xsd (EX-101.SCH) — 4KB
- sgmo-20240419_lab.xml (EX-101.LAB) — 7KB
- sgmo-20240419_pre.xml (EX-101.PRE) — 4KB
- sgmo-20240419_htm.xml (XML) — 96KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 47 DELINQUENT SECTION 16(a) REPORTS 49
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 50 Compensation Discussion and Analysis 50 Executive Summary 50 How We Determine Executive Compensation 55 Design of the Executive Compensation Program and Key Components 58 2023 Compensation Decisions 60 Additional Compensation Information 64 Table of Contents Page Compensation Committee Report 65 Summary Compensation Table 66 Grants of Plan-Based Awards 67 Employment Agreements and Compensation Arrangements 68 Outstanding Equity Awards at Fiscal Year-End 70 Option Exercises and Stock Vested 72 Pension Benefits 72 Nonqualified Deferred Compensation 72 Risk Assessment of Compensation Policies and Practices 72 Employment Contracts and Separation and Change in Control Arrangements 73 CEO Pay Ratio Disclosure 78 Pay Versus Performance 78 EQUITY COMPENSATION PLAN INFORMATION 82 REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS 83 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 84 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 85 HOUSEHOLDING OF PROXY MATERIALS 87 OTHER MATTERS 88 APPENDIX A: AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN A- 1 APPENDIX B: FORM OF CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF SANGAMO THERAPEUTICS, INC. (CERTIFICATE OF AMENDMENT) B- 1 Table of Contents SANGAMO THERAPEUTICS, INC. | 501 Canal Boulevard | Richmond, California 94804 PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS | To Be Held on June 4, 2024 Questions and Answers About These Proxy Materials and Voting Why am I receiving these materials? Our Board of Directors (referred to herein as the Board of Directors or the Board) is soliciting your proxy to vote at the Annual Meeting, including at any adjournments or postponements of the Annual Meeting. This Proxy Statement contains important information regarding the Annual Meeting, the proposals on which you are being asked to vote, information you may find useful in determinin